Eye-disease biotech Tarsier lists on NYSE under ticker TARX
What's the deal? Tarsier PharmaDealroom has a profile for this one. Try Dealroom →, an ophthalmology biotech, has gone public on the New York Stock Exchange under the ticker TARX. The listing was announced in July 2026.
What's the endgame? Tarsier is developing treatments for sight-threatening inflammatory eye diseases. Its lead platform is built on dazdotuftide, an immune-modulating compound designed to work without steroids.
The company is advancing both eye-drop and injectable formulations. The aim is to cut inflammation while avoiding steroid-related side effects.
Why now? Tarsier is targeting non-infectious anterior uveitis, an inflammatory eye condition. It sees large unmet need among patients with uveitis and its complication, glaucoma.
The signal: Steroids remain a mainstay for treating eye inflammation, but carry side effects. A public listing gives Tarsier the capital to test whether a steroid-free approach can reach patients who currently have few good options.
Read more: IT桔子
Image credit: Ivan Radic
